Will Increased Expenses Affect Bristol Myers' Performance?

Last month, Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of the latter’s investigational bispecific antibody BNT327 across numerous solid tumor types.While the collaboration strengthens BMY’s pipeline, the company will incur increased operating expenses.BMY will make an upfront payment of...